Journal of Diagnostics

Published by: Asian Medical Journals
Online ISSN: 2409-322X
Print ISSN: 2413-8371
Quick Submission    Login/Submit/Track

No. 2

Acute Renal Failure, Electrolyte and Acid-Base Changes in Three Cases with Ileostomy

Pages: 53-56
Find References

Finding References


Acute Renal Failure, Electrolyte and Acid-Base Changes in Three Cases with Ileostomy

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.98/2014.1.2/98.2.53.56

Fatih Mehmet Erdur , Yasemin Soyoral , Habib Emre , Huseyin Begenik , Esra Turan Canbaz , Ozgur Kemik

Export to    BibTeX   |   EndNote   |   RIS

  1. N. Beck-Kaltenbach, K. Voigt, and B. Rumstadt, "Renal impairment caused by temporary loop ileostomy," Int. J. Colorectal Dis., vol. 26, pp. 623-626, 2011.
  2. G. Hill, W. Mair, and J. Goligher, "Cause and management of high volume output salt depleting ileostomy," Br. J. Surg., vol. 62, pp. 720-6, 1975.
  3. N. Gallagher, D. Harrison, and A. Skyring, "Fluid and electrolyte disturbances in patients with long-established ileostomies," Gut., vol. 3, pp. 219-23, 1962.
  4. S. Feinberg, R. McLeod, and Z. Cohen, "Complications of loop ileostomy," Am J Surg., vol. 153, pp. 102–6, 1987.
  5. J. W. Wolfgang and A. S. Feliciano, "Acute electrolyte and acid-base disorders in patients with Ileostomies: A case series," Am J Kidney Dis., vol. 52, pp. 494-500, 2008.
  6. G. Hill, Normal ileostomy physiology. In: Hill GL (Eds). Ileostomy: Surgery, physiology and management. New York: Grune & Stratton, 1976.
  7. C. Newton, "The effect of codeine phosphate, lomotil, and isogel on ileostomy function," Gut., vol. 14, pp. 424-5, 1973.
  8. D. Saunders, M. Saunders, and J. Sillery, "Beneficial effects of glucose polymer and an H2-receptor blocker in a patient with a proximal ileostomy," Am. J. Gastroenterol., vol. 84, pp. 192-4, 1989.
Fatih Mehmet Erdur , Yasemin Soyoral , Habib Emre , Huseyin Begenik , Esra Turan Canbaz , Ozgur Kemik (2014). Acute Renal Failure, Electrolyte and Acid-Base Changes in Three Cases with Ileostomy. Journal of Diagnostics, 1(2): 53-56. DOI: 10.18488/journal.98/2014.1.2/98.2.53.56
Ileostomy is a standard surgical procedure performed in order to protect the anastomosis and reduce the complication risk in colorectal surgery. Dehydration is one of the most important complications of ileostomy and dehydration-induced renal failure. We present three ileostomy cases that had undergone bowel resection for small bowel perforation, two of which due to mesenteric ischemia, and the other one due to a gunshot injury, all three developing acute renal failure. As ileostomy patients carry the risk of life-threatening renal failure and electrolyte and acid-base changes due to dehydration, clinicians should follow-up these patients closely considering the possible complications of ileostomy.
Contribution/ Originality

Treatment of Adamantinoma in Tibial Diaphysis by Hemicortical Resection and Strut Allograft

Pages: 47-52
Find References

Finding References


Treatment of Adamantinoma in Tibial Diaphysis by Hemicortical Resection and Strut Allograft

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.98/2014.1.2/98.2.47.52

Mustafa Nazım Karalezli , Ismail Hakkı Korucu , Oguzhan Pekince , Serdar Toker

Export to    BibTeX   |   EndNote   |   RIS

  1. J. Mirra, Adamantinoma and fibrous dysplasia. Bone Tumors. Clinical, radiologic and pathologic correlations. Philadelphia: Lea & Febiger, 1989.
  2. R. Fechner and S. Mils, Tumors of the bones and joints. In: Atlas of tumor pathology, 3rd ed. Washington DC: Lippincott-Raven, 1993.
  3. N. Moon and H. Mori, "Adamantinoma of the appendicular skeleton – updated," Clin Orthop, vol. 204, p. 215, 1986.
  4. A. Qureshi, S. Shott, and B. Mallin, "Current trends in the management of adamantinoma of long bones. An international study," J Bone Joint Surg Am., vol. 82, pp. 1122 – 1131, 2000.
  5. M. Campanacci, A. Giunti, and F. Bertoni, "Adamantinoma of the long bones. The experience at the Istituto ortopedico Rizzoli," Am J Surg Pathol., vol. 5, pp. 533 – 542, 1981.
  6. M. Rock, J. Beabout, and K. Unni, "Adamantinoma," Orthopedics, vol. 6, pp. 472 – 477, 1983.
  7. M. Maki and N. Athanasou, "Osteofibrous dysplasia and adamantinoma: Correlation of protooncogene product and matrix protein expression," Hum Pathol., vol. 35, pp. 69 – 74, 2004.
  8. J. Bovée, L. Van Den Broek, and W. De Boer, "Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis," J Pathol., vol. 184, pp. 24 – 30, 1998.
  9. M. Manfrini, D. Vanel, and M. De Paolis, "Imaging of vascularized fibula autograft placed inside a massive allograft in reconstruction of lower limb bone tumors," Am J Roentgenol, vol. 182, pp. 963 - 970, 2004.
  10. S. Green, J. Jackson, and D. Wall, "Management of segmental defects by the Ilizarov intercalary bone transport method," Clin Orthop Relat Res., vol. 280, pp. 136 – 142, 1992.
  11. A. Mavrogenis, V. Sakellariou, H. Tsibidakis, and P. Papagelopoulos, "Adamantinoma of the tibia treated with a new intramedullary diaphyseal segmental defect implant," J Int Med Res., vol. 37, pp. 1238-45, 2009.
  12. D. Donati, M. Di Liddo, and M. Zavatta, "Massive bone allograft reconstruction in high-grade osteosarcoma," Clin Orthop Relat Res., vol. 377, pp. 186 – 194, 2000.
  13. R. J. Thompson, A. Garg, and D. Clohisy, "Fractures in large-segment allografts," Clin Orthop Relat Res., vol. 370, pp. 227 – 235, 2000.
  14. R. Deijkers, R. Bloem, P. Hogendoorn, J. Verlaan, H. Kroon, and A. Taminiau, "Hemicortical allograft reconstruction after resection of low-grade malignant bone tumours," J Bone Joint Surg (Br), vol. 84, pp. 1009-14, 2002.
Mustafa Nazım Karalezli , Ismail Hakkı Korucu , Oguzhan Pekince , Serdar Toker (2014). Treatment of Adamantinoma in Tibial Diaphysis by Hemicortical Resection and Strut Allograft. Journal of Diagnostics, 1(2): 47-52. DOI: 10.18488/journal.98/2014.1.2/98.2.47.52
Introduction: Adamantinoma is a primary low-grade, malignant bone tumor, of unknown histogenesis which is a rare neoplasm, comprise only 0.1–0.5% of all primary bonetumors. It is slightly more common in men than women, with a ratio of 5:4. Wide tumour resection and limb salvage is the treatment of choice. Case report: A 24 year female reffered with chief complaints of pain and limping lasting for approximately 2 years. Plain X-ray showed an expansile multicystic lesion at the diaphysis of the left tibia anterior cortex with  periosteal reaction . We used an oscillating bone saw to perform a total resection of the lesion preserving the anterior cortex. Tibial defect created with this resection was replaced with a 14 cm. long strut cadaveric femoral allograft that fixed to tibia with a dynamic commpresive plate (DCP) and screws. Discussion: In surgical treatment of Adamantinoma, total resection was not performed and remain intact posterior cortex to increased the patient satisfaction, at the same time, bone fixation and early weight bearing at the postoperative. We believe that the defect will be able to union with appropriate fixation of the allograft also be long size. 
Contribution/ Originality

Chondrosarcoma of the Upper Extremity of the Humerus: A Case Report

Pages: 42-46
Find References

Finding References


Chondrosarcoma of the Upper Extremity of the Humerus: A Case Report

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.98/2014.1.2/98.2.42.46

Abdelilah Mouhsine , Hicham Sallahi , Ahmed Belkouch , El Mehdi Atmane , Redouane Rokhssi , Youssef Berrada , Khalid Koulali , Lahcen Belyamani , Abdelghani ElFikri , Mbarek Mahfoudi

Export to    BibTeX   |   EndNote   |   RIS

  1. D. Dahlin, Bone tumors: General aspect and data on 6 221 cases. Springfield: CC Thomas, 1978.
  2. M. Campanacci, Bone and soft tissue tumors. New York: Springer-Verlag, 1986.
  3. F. Lee, H. Mankin, G. Fondren, M. Gebhardt, D. Springfield, and A. Rosenberg, "Chondrosarcoma of bone. An assessment of outcome," J Bone Joint Surg Am., vol. 81, pp. 326-338, 1999.
  4. E. Ucla, B. Tomeno, and M. Forest, "Facteurs du pronostic tumoral dans les chondrosarcomes de l’appareil locomoteur," Rev Chir Orthop., vol. 77, pp. 301-311, 1991.
  5. M. Forest, Orthopedic surgical pathology: Diagnosis of tumors and pseudotumoral lesions of bone and joint. In : Forest M, Tomeno B, Vanel D Eds. Edinburgh: Churchill Livingstone, 1998.
  6. H. Evans, A. Ayala, and M. Romsdhal, "Prognostic factors in chondrosarcoma of bone. Clinicopathologic analysis with emphasis on histologic grading," Cancer, vol. 40, pp. 818-831, 1977.
  7. D. Springfield, M. Gebhardt, and M. McGuire, "Chondrosarcoma: A review," J Bone Joint Surg Am., vol. 78, pp. 141-149, 1996.
  8. K. Unni, D. Dahlin, J. Beabout, and F. Sim, "Chondrosarcoma: Clear-cell variant. A report of sixteen cases," J Bone Joint Surg Am., vol. 58, pp. 676-683, 1976.
  9. J. Bovée, R. Van Der Heul, A. Taminiau, and P. Hogendoorn, "Chondrosarcomaof the phalanx: Alocally aggressive lesion with minimal metastatic potential: A report of 35 cases and a review of the literature [See Comments]," Cancer, vol. 86, pp. 1724-1732, 1999.
  10. T. Cawte, G. Steiner, J. Beltran, and H. Dorfman, "Chondrosarcoma of the short tubular bones of the hands and feet," Skeletal Radiol., vol. 27, pp. 625-632, 1998.
  11. R. Gaulke and P. Preisser, "Secondary chondrosarcoma of the hand. Case report and review of the literature," Handchir Mikrochir Plast Chir., vol. 29, pp. 251-255, 1997.
  12. D. Pritchard, R. Lunke, W. Taylor, D. Dahlin, and B. Medley, "Chondrosarcoma: A clinicopathologic and statistic analysis," Cancer, vol. 45, pp. 149-157, 1980.
  13. R. Marcove, V. Mike, R. Hutter, A. Huvos, H. Shoji, and T. Miller, "Chondrosarcoma of thre pelvis and upper end of the femur," J Bone Joint Surg Am., vol. 54, pp. 561-572, 1972.
  14. Encyclopédie Médico-Chirurgical, "Appareil locomoteur," Chondrosarcomes Intraosseux, vol. 14-716, pp. 10-12.
Abdelilah Mouhsine , Hicham Sallahi , Ahmed Belkouch , El Mehdi Atmane , Redouane Rokhssi , Youssef Berrada , Khalid Koulali , Lahcen Belyamani , Abdelghani ElFikri , Mbarek Mahfoudi (2014). Chondrosarcoma of the Upper Extremity of the Humerus: A Case Report. Journal of Diagnostics, 1(2): 42-46. DOI: 10.18488/journal.98/2014.1.2/98.2.42.46
Chondrosarcomas are frequent bone tumors, just after osteosarcomas, they represent 11 to 22% of all bone tumors. Proximal humerus localization occurs in about 9% of cases, the clinical picture is variable, imagery helps to establish the diagnosis, to give an exact lesion assessment and to guide therapeutic attitude and post treatment control. Confirmation is set by histology. 
We highlight through this case presentation clinical and radiological aspects of these tumors.

Contribution/ Originality

Serum Rankl/Osteoprotegerin Complex and Endothelial Progenitor Cells in Chronic Heart Failure

Pages: 28-41
Find References

Finding References


Serum Rankl/Osteoprotegerin Complex and Endothelial Progenitor Cells in Chronic Heart Failure

Search :
Google Scholor
Search :
Microsoft Academic Search
Cite

DOI: 10.18488/journal.98/2014.1.2/98.2.28.41

Alexander E. Berezin , Alexander A. Kremzer

Export to    BibTeX   |   EndNote   |   RIS

  1. V. L. Roger, "The heart failure epidemic," Int J Environ Res Public Health, vol. 7, pp. 1807–1830, 2010.
  2. P. Rajendran, T. Rengarajan, and J. Thangavel, "The vascular endothelium and human diseases," Int J Biol Sci., vol. 9, pp. 1057-69, 2013.
  3. Y. Matsuzawa, S. Sugiyama, and H. Sumida, "Peripheral endothelial function and cardiovascular events in high-risk patients," J Am Heart Assoc., vol. 2, p. e000426, 2013.
  4. J. Wang and T. Guo, "Metabolic remodeling in chronic heart failure," J Zhejiang Univ Sci B., vol. 14, pp. 688–95, 2013.
  5. C. Balion, A. Don-Wauchope, and S. Hill, "Use of natriuretic peptide measurement in the management of heart failure," Comparative Effectiveness Reviews, No.126. AHRQ Publication No. 13(14)-EHC118-EF, 2013.
  6. J. M. Hill, G. Zalos, and J. P. Halcox, "Circulating endothelial progenitor cells, vascular function, and cardiovascular risk," N Engl J Med., vol. 348, pp. 593-600, 2003.
  7. A. C. Alba, S. D. Lalonde, and V. Rao, "Changes in circulating progenitor cells are associated with outcome in heart failure patients: A longitudinal study," Can J Cardiol., vol. 29, pp. 1657-64, 2013.
  8. C. Alba, D. H. Delgado, and V. Rao, "Are endothelial progenitor cells a prognostic factor in patients with heart failure?," Expert Rev Cardiovasc Ther., vol. 10, pp. 167-175, 2012.
  9. T. E. Hadj Othmane, G. Speer, and B. Fekete, "Osteoprotegerin: Regulator, protector and marker," Orv Hetil, vol. 149, pp. 1971-80, 2008.
  10. G. Loncar, B. Bozic, and V. Cvorovic, "Relationship between RANKL and neuroendocrine activation in elderly males with heart failure," Endocrine, vol. 37, pp. 148-56, 2010.
  11. A. E. Kearns, S. Khosla, and P. J. Kostenuik, "Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease," Endocr Rev., vol. 29, pp. 155-92, 2008.
  12. D. M. Leistner, F. H. Seeger, and A. Fischer, "Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis," Circ Heart Fail, vol. 5, pp. 769-77, 2012.
  13. K. K. Doumouchtsis, A. I. Kostakis, and S. K. Doumouchtsis, "sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients," J Endocrinol Invest., vol. 30, pp. 762-6, 2007.
  14. J. J. V. McMurray, S. Adamopoulos, and S. D. Anker, "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure," Eur Heart J., vol. 33, pp. 1787–847, 2012.
  15. D. A. Bluemke, S. A. chenbach, and M. Budoff, "Noninvasive coronary artery imaging: Magnetic resonance angiography and multidetector computed tomography angiography. A scientific statement from the American heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young," Circulation, vol. 118, pp. 586–606, 2008.
  16. M. J. Budoff, S. Achenbach, and R. S. Blumenthal, "Intervention AHACoCIa, intervention AHACoCRa, American heart association committee on cardiac imaging CoCC. Assessment of coronary artery disease by cardiac computed tomography: A scientific statement from the American heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on Cardiac imaging, council on clinical cardiology," Circulation, vol. 114, pp. 1761-1791, 2006.
  17. N. B. Schiller, P. M. Shah, and M. Crawford, "Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms," J Am Soc Echocardiogr., vol. 2, pp. 358–367, 1989.
  18. D. Pellerin, R. Sharma, P. Elliott, and C. Veyrat, "Tissue doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function," Heart, vol. 89, pp. 39-17, 2003.
  19. A. S. Levey, L. A. Stevens, and C. H. Schmid, "for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), A new equation to estimate glomerular filtration rate," Ann Intern Med., vol. 150, pp. 604-12, 2009.
  20. J. W. Tung, D. R. Parks, and W. A. Moore, "New approaches to fluorescence compensation and visualization of FACS data," Clin Immunol., vol. 11, pp. 277-83, 2004.
  21. Balion, A. Don-Wauchope, and S. Hill, "Use of natriuretic peptide measurement in the management of heart failure," Comparative Effectiveness Reviews No. 126. AHRQ Publication No. 13(14)-EHC118-EF, 2013.
  22. Vesbianu, C. Vesbianu, P. Bernstein, and R. Kouides, "Plasma brain natriuretic peptide—an independent predictor of mortality and rehospitalization in congestive heart failure - a meta-analysis," World Heart J., vol. 1, pp. 349–54, 2008.
  23. G. Lippi and G. Cervellin, "Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers," Crit Rev Clin Lab Sci., vol. 51, pp. 13-29, 2014.
  24. T. Ueland, A. Yndestad, and E. Øie, "Dysregulated osteoprotegerin/ RANK ligand/RANK axis in clinical and experimental heart failure," Circulation, vol. 111, pp. 2461-8, 2005.
  25. A. Yndestad, D. J. Kristian, and E. H. Geir, "Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure," Cardiovasc Res., vol. 54, pp. 175–82, 2002.
  26. M. Anderson, E. Maraskovsky, and W. L. Billingsley, "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," Nature, vol. 390, pp. 175–9, 1997.
  27. S. Kiechl, G. Schett, and J. Schwaiger, "Soluble receptor activator of nuclear factor-?B ligand and risk for cardiovascular disease," Circulation, vol. 116, pp. 385–91, 2007.
  28. A. Van Campenhout and J. Golledge, "Osteoprotegerin, vascular calcification and atherosclerosis," Atherosclerosis, vol. 204, pp. 321–329, 2009.
  29. S. Kiechl, G. Schett, and G. Wenning, "Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease," Circulation, vol. 109, pp. 2175–80, 2004.
  30. A. M. Blázquez-Medela, L. García-Ortiz, and M. A. Gómez-Marcos, "Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes," Eur. J Clin. Invest., vol. 42, pp. 548–56, 2012.
  31. S. Jono, Y. Ikari, and A. Shioi, "Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease," Circulation, vol. 106, pp. 1192-4, 2002.
  32. M. Schoppet, A. M. Sattler, and J. R. Schaefer, "Increased osteoprotegerin serum levels in men with coronary artery disease," J Clin Endocrinol Metab., vol. 88, pp. 1024-8, 2003.
  33. T. Ueland, R. Jemtland, and K. Godang, "The prognostic value of osteoprotegerin in patients with acute myocardial infarction," J Am Coll Cardiol., vol. 44, pp. 1970-6, 2004.
  34. C. Giaginis, A. Papadopouli, and A. Zira, "Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor ?B ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis," Med Sci Monit., vol. 18, pp. CR597-604, 2012.
  35. M. Bjerre, K. Munk, and A. D. Sloth, "High osteoprotegerin levels predict MACCE in STEMI patients, but are not associated with myocardial salvage," Scand Cardiovasc J., vol. 1, p. 7, 2014.
  36. M. Bjerre, "Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications," Springerplus, vol. 2, p. 658, 2013.
  37. B. B. Løgstrup, D. E. Høfsten, and T. B. Christophersen, "Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction," Coron Artery Dis., vol. 24, pp. 487-92, 2013.
  38. R. Mogelvang, S. Haahr-Pedersen, and M. Bjerre, "Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hs-CRP," Heart, vol. 99, pp. 106-10, 2013.
  39. M. Montagnana, G. Lippi, E. Danese, and G. C. Guidi, "The role of osteoprotegerin in cardiovascular disease," Ann Med., vol. 45, pp. 254-64, 2013.
  40. Schweikle, T. Baessler, and S. Yildirim, "Osteoprotegerin positively regulates hematopoietic progenitor cells," Curr Stem Cell Res Ther., vol. 7, pp. 72-7, 2012.
  41. J. Y. Kim, Y. J. Park, and K. J. Kim, "Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress," Arthritis Rheum., vol. 65, pp. 2172-82, 2013.
  42. L. Liu, Z. Z. Liu, and H. Chen, "Oxidized low-density lipoprotein and ?-glycerophosphate synergistically induce endothelial progenitor cell ossification," Acta Pharmacol Sin., vol. 32, pp. 1491-7, 2011.
  43. Y. Mei, M. D. Thompson, R. A. Cohen, and X. Tong, "Autophagy and oxidative stress in cardiovascular diseases," Biochim Biophys Acta, vol. pii: S0925-4439, pp. 00133-1, 2014.
  44. N. Parajuli, V. B. Patel, and W. Wang, "Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure," Clin Sci (Lond), vol. 127, pp. 331-40, 2014.
Alexander E. Berezin , Alexander A. Kremzer (2014). Serum Rankl/Osteoprotegerin Complex and Endothelial Progenitor Cells in Chronic Heart Failure. Journal of Diagnostics, 1(2): 28-41. DOI: 10.18488/journal.98/2014.1.2/98.2.28.41
The objectiveof this study was to assess an interrelationship serum RANKL/OPG complex with counts of circulating pro-angiogenic endothelial progenitor cells (EPCs) labeled as CD14+CD309+, and CD14+CD309+Tie2+ in patients with ischemic chronic heart failure (CHF).
Methods: The study retrospectively evolved 153 patients (86 males) aged 48 to 62 years with exiting proven stable coronary artery disease (CAD). Systolic or diastolic CHF was defined among 109 (71.2%) patients. Twenty five 25 individuals were included in the control group. Circulating RANKL (sRANKL) and OPG were measured by high-sensitive ELISA kit at baseline. EPC populations were labeled by flow cytofluorimetry per High-Definition Fluorescence Activated Cell Sorter methodology.
Results: Numerous of EPCs with phenotypes of CD14+CD309+ and CD14+CD309+Tie2+ were significantly lower in CAD patients when compared with healthy subjects. The trend to significant decrease of EPC numerous depending presence of CHF was found. The sRANKLlevel, OPG level, and sRANKL / OPG ratio were significantly higher in CHF subjects as compared to those without CHF (P=0.001). On multivariate analysis, CHF, sRANKL/OPG ratio, OPG, and NT-pro-BNP remained as independent predictors of decreased EPCs with phenotypes of CD14+CD309+ and CD14+CD309+Tie2+. When sRANKL/OPG ratio was added to the standard predictive model (CHF) improved relative integrated discrimination indices by 12.5% for CD14+CD309+ depletion, as well as by 17.3% for CD14+CD309+Tie2+depletion were found. 
Conclusion: We found that sRANKL/OPG ratio remained statistically significant predictor for depletion of pro-angiogenicEPCsin CAD patients.

Contribution/ Originality
The paper’s primary contribution is finding that inflammatory cytokines, such as components of RANKL/OPG complex, areable to negatively modulate the level of circulating pro-angiogenicendothelial progenitor cells labeled as CD14+CD309+, and CD14+CD309+Tie2+ and thereby reduce a reparative potency of vasculature in heart failure patients.